Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BOLD vs ANAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANAB Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ANAB Overall Winner 6-Pillar Tally: BOLD 2 – 3 ANAB (1 Tie) Matrix Metrics: BOLD 4 – 6 ANAB

As of Nov 20, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas ANAB carries 54.8/100 (HOLD) at $46.63 (35.7x Forward P/E, 15.0% operating margin).

  • Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. BOLD 36.8/100 SELL) and 1.00β · 34% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ANAB is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BOLD vs ANAB
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52
ANAB NASDAQ Head-to-Head Winner
AnaptysBio, Inc. Common Stock
Pharmaceutical Preparations
$46.63
-1.62% 1D
Market Cap $1.4B
TTM Revenue $60M
Forward P/E 35.7x
Beta / 30D Vol 1.00β · 34% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 59.0 Fund 61.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.5 · SMA20: $47.58 · SMA50: $48.88

6-Pillar Scorecard Institutional Category Breakdown (BOLD 2 – 3 ANAB)

Columns: Metric · BOLD · ANAB
1. Valuation Multiples ANAB
Forward P/E N/M 35.7x
Trailing P/E N/M 7.3x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BOLD
Revenue Growth (YoY) +0.0% -60.3%
Earnings Growth (YoY) +0.0% -78.8%
TTM Revenue (USD) N/A $60M
Market Cap $56.2M $1.4B
3. Profitability & Quality ANAB
Gross Margin N/A N/A
Operating Margin 0.0% 15.0%
Net Profit Margin 0.0% 417.6%
Return on Equity (ROE) -64.6% -114.5%
4. Balance Sheet & Cash Flow ANAB
Cash Generation (TTM) -$48M $433M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Debt (0.56x D/E) $1.51B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 84.5% (18th %ile)
Put/Call OI Skew N/A 0.93x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BOLD (4) vs ANAB (6)
Institutional Metric BOLD ANAB Criterion Row Edge
Market Capitalization
Scale
$56.2M $1.4B Larger Scale ANAB
Trailing P/E Ratio
Valuation
N/M 7.3x Lower Multiple ANAB
Forward P/E Ratio
Valuation
N/M 35.7x Lower Multiple ANAB
Revenue Growth (YoY)
Growth
+0.0% -60.3% Higher Growth BOLD
Operating Margin (TTM)
Profitability
0.0% 15.0% Higher Margin ANAB
Net Profit Margin
Profitability
0.0% 417.6% Higher Margin ANAB
Return on Equity (ROE)
Capital Efficiency
-64.6% -114.5% Higher ROE BOLD
52-Week Range Position
Momentum
62% ($1–$3) 34% ($33–$73) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
-0.08β · 28% Vol 1.00β · 34% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 54.8 / 100 (HOLD) Higher Composite ANAB
Trailing 12M Revenue (USD)
Operating Scale
N/A $60M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($31M Net Debt (0.56x D/E)) $433M ($1.51B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANAB +1.86 pp
BOLD: -4.92% · ANAB: -3.06%
3M Horizon ANAB +1.41 pp
BOLD: -21.62% · ANAB: -20.21%
6M Horizon BOLD +83.02 pp
BOLD: +61.11% · ANAB: -21.91%
1Y Horizon BOLD +75.75 pp
BOLD: +101.74% · ANAB: +25.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs ANAB. Trailing 12-month operating profitability (BOLD 0.0% vs ANAB 15.0%) and valuation multiples (BOLD N/M vs ANAB 35.7x Forward P/E) are benchmarked directly in Pillar 4 below.

BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M
ANAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$60M
Gross MarginN/A
Op. Margin15.0%
ROE / Fwd P/E-114.5% · 35.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANAB BREAKDOWN
93d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.93x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ANAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANAB Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BOLD vs ANAB Key Questions & Quantitative Answers

As of Nov 20, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas ANAB carries 54.8/100 (HOLD) at $46.63 (35.7x Forward P/E, 15.0% operating margin). Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. BOLD 36.8/100 SELL) and 1.00β · 34% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ANAB is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BOLD leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANAB at -60.3% YoY revenue growth and -78.8% YoY earnings growth on $60M TTM revenue (N/A gross margin, 15.0% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $60M for ANAB. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANAB.

ANAB screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANAB trades at 35.7x Forward P/E, 7.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus ANAB (-114.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, ANAB carries 84.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.93x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.00β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.